Chemiluminescence Immunoassay Market Size, Share & Trends Analysis By Product (Consumables, Instruments and Software & Services), By Application (Cardiology, Therapeutic Drug Monitoring, Oncology, Endocrinology, Autoimmune Disease, Infectious Disease and Others), By End-User (Clinical Laboratories, Hospitals, Pharmaceutical & Biotechnology Companies and Others) - Global Industry Analysis, Trends, Segment Forecasts, Regional Outlook 2024 - 2033
The global chemiluminescence immunoassay market size was valued at USD 7.22 billion in 2023 and is anticipated to reach around USD 15.15 billion by 2033, growing at a CAGR of 7.7% from 2024 to 2033.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
The U.S. chemiluminescence immunoassay market size was estimated at USD 2.59 billion in 2023 and is predicted to be worth around USD 5.69 billion by 2033, at a CAGR of 8.2% from 2024 to 2033.
North America seized the substantial market stake globally in 2023 and is projected to mirror this trend during the assessment period. Significant influences backing to its governance are the existence of established healthcare infrastructure, high acceptance of cutting-edge chemiluminescence immunoassay solutions, and snowballing pervasiveness of chronic diseases among others. Additionally, augmented availability of novel CLIA systems in the U.S. on account of existence of crucial market participants like Beckman Coulter, Inc., Abbott Laboratories, Roche and DiaSorinis further likely to subsidize the growth of the market in the North America.
Asia Pacific is prospective to be an extremely profitable market for the chemiluminescence immunoassay analyzers market and it is anticipated to develop at a rapid growth rate throughout the estimate period. Huge population base and escalation in occurrence of infectious and chronic diseases augments requirement for diagnostic testing in the APAC. Besides, promising government initiative to progress healthcare infrastructure is expected to supplement the growth of the market.
The Europe chemiluminescence immunoassay market size was calculated at USD 1.83 billion in 2023 and is projected to expand around USD 4.06 billion by 2033, poised to grow at a CAGR of 8.3% from 2024 to 2033.
| Year | Market Size (USD Billion) |
| 2023 | 1.83 |
| 2024 | 1.99 |
| 2025 | 2.15 |
| 2026 | 2.33 |
| 2027 | 2.52 |
| 2028 | 2.73 |
| 2029 | 2.96 |
| 2030 | 3.20 |
| 2031 | 3.46 |
| 2032 | 3.75 |
| 2033 | 4.06 |
Diagnostic technology is budding rapidly, and over the last decade, considerable progress has been made in the identification of antibodies, progressively impending this sort of diagnostic to that of automated clinical chemistry laboratory. The number of tests integrating chemiluminescence immunoassay Analyzers practices is estimated to magnify on account of technological advancements in disease diagnosis, upsurge in demand for treatment monitoring and precautionary diagnosis. Subsequently, requirement for high throughput facilities are also increasing. Furthermore, large-scale laboratories are capturing benefit of service and quality constraints confronted by small and mid-volume laboratories to seize a bigger chunk of the market by means of CLIA methods.
Companion diagnostics comprise assays or tests proposed to support healthcare providers in taking treatment decisions for patients on the basis of finest response to therapy. The co-development of companion diagnostics along with therapeutic products has the latent to meaningfully modify the drug development process and commercialize drug candidates by getting safer drugs with improved therapeutic effectiveness cost-effectively and quickly. With an increase in the demand for high-priced specialist therapies and safer drugs, the market for companion diagnostics is expected to showcase a high growth potential.The Novel coronavirus epidemic is expected to influence market projections for the chemiluminescence immunoassays market. This is due to its possible application in eliminating the disease. Research is underway for the development of the peptide-based magnetic CLIA for serological diagnosis of the COVID-19 virus. This is a noteworthy development since this is the second diagnostic test afterwards real-time RT-PCR, which is the only existing laboratory test to check probable cases of contamination.
| Report Coverage | Details |
| Market Size in 2023 | USD 7.22 Billion |
| Market Size by 2033 | USD 15.15 Billion |
| Growth Rate from 2024 to 2033 | CAGR of 7.7% |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Product Type, By Application Type, and By End User Type |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Numerous applications of chemiluminescence immunoassay market comprises of disorders, endocrine infectious diseases, oncology, cardiovascular disorders, hepatitis and retrovirus, allergy, drug discovery & development autoimmunity, and others. Endocrine gathered considerable market share in terms of revenue in 2023 and it is predicted to reflect this tendency throughout the estimate period. Foremost influences accountable for the governance of this application segment are incessant inventions in test offerings and extensive product offerings of chief and local manufacturers.
Among different product segments analyzed in this research study, consumables segment garnered substantial share more than 70% of the total market revenue generated in 2023. This segment is predicted to hold its domination over the prediction period. This growth can be credited to augmented requirement for consumables including stains and reagents in the area of endocrinology, therapeutic drug monitoring, and disease analysis.
In terms of several end-users, hospitals grasp majority of the market chunk and reported prime revenue share of more than 37% in 2023. This governance is credited to the cumulative need for chemiluminescence immunoassay solutions in hospitals and intensifying hospital visits on account of mounting occurrence of infectious diseases and cancer. Correspondingly, the growing hospitalization owed to outburst of novel coronavirus is anticipated to increase the requirement for chemiluminescence immunoassay solutions in the hospital segment. Snowballing amount of applications of automated CLIA analyzers in oncology, therapeutic drug monitoring, and companion diagnostics and emergence of integrated modules of automated CLIA analyzers are projected to fuel the growth of hospitals segment throughout the estimate period.
Segments Covered in the Report
By Product
By Application
By End-use
By Regional Outlook
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Chemiluminescence Immunoassay Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
Chapter 5. COVID 19 Impact on Chemiluminescence Immunoassay Market
5.1. Covid-19: Chemiluminescence Immunoassay Industry Impact
5.2. Chemiluminescence Immunoassay Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Chemiluminescence Immunoassay Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Chemiluminescence Immunoassay Market Players to deal with Covid-19 Pandemic Scenario
Chapter 6. Chemiluminescence Immunoassay Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Upsurge in demand for treatment monitoring and precautionary diagnosis
6.1.1.2. Growth in technological advancements in disease diagnosis and COVID19 pandemic
6.1.2. Market Restraints
6.1.2.1. Restraint 1
6.1.3. Market Opportunities
6.1.3.1. Opportunity 1
6.1.3.2. Opportunity 2
Chapter 7. Global Chemiluminescence Immunoassay Market: Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Chemiluminescence Immunoassay Market Revenue by Market Players
7.1.1.2. Chemiluminescence Immunoassay Market Revenue Market Share by Market Players
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Product Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Product TypeSuppliers
7.1.3.2. List of End-users
Chapter 8. Global Chemiluminescence Immunoassay Market, By Product Type
8.1. Chemiluminescence Immunoassay Market, by Component, 2024-2033
8.1.1. Consumables
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Instruments
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Software & Services
8.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Chemiluminescence Immunoassay Market, By Application
9.1. Chemiluminescence Immunoassay Market, by Application, 2024-2033
9.1.1. Cardiology
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Therapeutic Drug Monitoring
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Oncology
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Endocrinology
9.1.4.1. Market Revenue and Forecast (2021-2033)
9.1.5. Autoimmune Disease
9.1.5.1. Market Revenue and Forecast (2021-2033)
9.1.6. Infectious Disease
9.1.6.1. Market Revenue and Forecast (2021-2033)
9.1.7. Others
9.1.7.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Chemiluminescence Immunoassay Market, By End-user
10.1. Chemiluminescence Immunoassay Market, by End-user, 2024-2033
10.1.1. Clinical Laboratories
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Hospitals
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Pharmaceutical & Biotechnology Companies
10.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global Chemiluminescence Immunoassay Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue Forecast by Product Type(2021-2033)
11.1.2. Market Revenue Forecast by Application (2021-2033)
11.1.3. Market Revenue Forecast by End-user (2021-2033)
11.1.4. U.S
11.1.4.1. Market Revenue Forecast (2021-2033)
11.1.5. Canada
11.1.5.1. Market Revenue Forecast (2021-2033)
11.2. Europe
11.2.1. Market Revenue Forecast by Product Type(2021-2033)
11.2.2. Market Revenue Forecast by Application (2021-2033)
11.2.3. Market Revenue Forecast by End-user (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue Forecast (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue Forecast (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue Forecast (2021-2033)
11.2.7. Rest of EU
11.2.7.1. Market Revenue Forecast (2021-2033)
11.3. Asia Pacific (APAC)
11.3.1. Market Revenue Forecast by Product Type(2021-2033)
11.3.2. Market Revenue Forecast by Application (2021-2033)
11.3.3. Market Revenue Forecast by End-user (2021-2033)
11.3.4. China
11.3.4.1. Market Revenue Forecast (2021-2033)
11.3.5. India
11.3.5.1. Market Revenue Forecast (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue Forecast (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue Forecast (2021-2033)
11.4. LATAM
11.4.1. Market Revenue Forecast by Product Type(2021-2033)
11.4.2. Market Revenue Forecast by Application (2021-2033)
11.4.3. Market Revenue Forecast by End-user (2021-2033)
11.4.4. Brazil
11.4.4.1. Market Revenue Forecast (2021-2033)
11.4.5. Rest of LATAM
11.4.5.1. Market Revenue Forecast (2021-2033)
11.5. Middle East and Africa (MEA)
11.5.1. Market Revenue Forecast by Product Type(2021-2033)
11.5.2. Market Revenue Forecast by Application (2021-2033)
11.5.3. Market Revenue Forecast by End-user (2021-2033)
11.5.4. GCC
11.5.4.1. Market Revenue Forecast (2021-2033)
11.5.5. North Africa
11.5.5.1. Market Revenue Forecast (2021-2033)
11.5.6. South Africa
11.5.6.1. Market Revenue Forecast (2021-2033)
11.5.7. Rest of MEA
11.5.7.1. Market Revenue Forecast (2021-2033)
Chapter 12. Company Profiles
12.1. F. Hoffmann-La Roche AG
12.1.1. Company Overview, Business Information, Regional Presence
12.1.2. Product Portfolio Analysis
12.1.2.1. Product Details, Specification, Application
12.1.3. Revenue, Price, and Gross Margin
12.1.4. Recent Developments and Strategies
12.2. Siemens Healthineers
12.2.1. Company Overview, Business Information, Regional Presence
12.2.2. Product Portfolio Analysis
12.2.2.1. Product Details, Specification, Application
12.2.3. Revenue, Price, and Gross Margin
12.2.4. Recent Developments and Strategies
12.3. Abbott Laboratories
12.3.1. Company Overview, Business Information, Regional Presence
12.3.2. Product Portfolio Analysis
12.3.2.1. Product Details, Specification, Application
12.3.3. Revenue, Price, and Gross Margin
12.3.4. Recent Developments and Strategies
12.4. DiaSorin S.p.A.
12.4.1. Company Overview, Business Information, Regional Presence
12.4.2. Product Portfolio Analysis
12.4.2.1. Product Details, Specification, Application
12.4.3. Revenue, Price, and Gross Margin
12.4.4. Recent Developments and Strategies
12.5. Ortho Clinical Diagnostics
12.5.1. Company Overview, Business Information, Regional Presence
12.5.2. Product Portfolio Analysis
12.5.2.1. Product Details, Specification, Application
12.5.3. Revenue, Price, and Gross Margin
12.5.4. Recent Developments and Strategies
12.6. Immunodiagnostic Systems
12.6.1. Company Overview, Business Information, Regional Presence
12.6.2. Product Portfolio Analysis
12.6.2.1. Product Details, Specification, Application
12.6.3. Revenue, Price, and Gross Margin
12.6.4. Recent Developments and Strategies
12.7. Beckman Coulter Inc.
12.7.1. Company Overview, Business Information, Regional Presence
12.7.2. Product Portfolio Analysis
12.7.2.1. Product Details, Specification, Application
12.7.3. Revenue, Price, and Gross Margin
12.7.4. Recent Developments and Strategies
12.8. Inova Diagnostics, Inc.
12.8.1. Company Overview, Business Information, Regional Presence
12.8.2. Product Portfolio Analysis
12.8.2.1. Product Details, Specification, Application
12.8.3. Revenue, Price, and Gross Margin
12.8.4. Recent Developments and Strategies
12.9. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
12.9.1. Company Overview, Business Information, Regional Presence
12.9.2. Product Portfolio Analysis
12.9.2.1. Product Details, Specification, Application
12.9.3. Revenue, Price, and Gross Margin
12.9.4. Recent Developments and Strategies
12.10. Maccura Biotechnology Co., Ltd
12.10.1. Company Overview, Business Information, Regional Presence
12.10.2. Product Portfolio Analysis
12.10.2.1. Product Details, Specification, Application
12.10.3. Revenue, Price, and Gross Margin
12.10.4. Recent Developments and Strategies
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
